Transine has ambitious plans for developing and exploiting the SINEUP® technology across a broad range of applications which are enabled by expert investors, Takeda Ventures, Inc. and the Dementia Discovery Fund.
The Dementia Discovery Fund (DDF) is a £250m specialist venture capital fund that invests in, and creates, new biotech companies to deliver high impact therapeutics for age-related dementias.
Takeda Ventures, Inc. focuses on high-calibre therapeutic and platform based, early-stage opportunities around the world. It concentrates on areas aligned with Takeda’s R&D focus including oncology, gastroenterology, neuroscience, and rare disease.
Epidarex is a transatlantic venture capital firm led by a diverse team of early-stage investors building breakthrough life science companies in emerging hubs. We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success. Epidarex builds the extraordinary.
For more information about Transine, please email our team via email@example.com or contact us below.